483
Baxter Oncology GmbHBaxter Oncology GmbH – FDA 483, Nov 5, 2019
Record Details
An FDA inspection of Baxter Oncology GmbH in Halle (Westf.), Germany, revealed significant deficiencies across multiple areas of drug product manufacturing. Key issues included failures in aseptic processing procedures, inadequate quality control oversight, and insufficient validation of cleaning processes, visual inspection, and critical utilities. The firm also demonstrated a lack of established accuracy for test methods and inadequate protection for electronic data acquisition systems.
View Company Profile
ID · f8379713-5f2d-4c65-9d44-6d8d24e6bc75
Other documents for Baxter Oncology GmbH
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.